Show simple item record

dc.contributor.authorCook, Natalie
dc.contributor.authorBanerji, U
dc.contributor.authorEvans, J
dc.contributor.authorBiondo, A
dc.contributor.authorGermetaki, Theodora
dc.contributor.authorRandhawa, M
dc.contributor.authorGodfrey, L
dc.contributor.authorLeslie, S
dc.contributor.authorJeffrey, P
dc.contributor.authorRigby, M
dc.contributor.authorBennett, G
dc.contributor.authorBlakemore, S
dc.contributor.authorKoehler, M
dc.contributor.authorNiewiarowski, A
dc.contributor.authorPittman, M
dc.contributor.authorSymeonides, SN
dc.date.accessioned2019-12-09T17:23:29Z
dc.date.available2019-12-09T17:23:29Z
dc.date.issued2019en
dc.identifier.citationCook N, Banerji U, Evans J, Biondo A, Germetaki T, Randhawa M, et al. 464P Pharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours. Annals of Oncology. 2019;30(Supplement_5):174.en
dc.identifier.doi10.1093/annonc/mdz244.026en
dc.identifier.urihttp://hdl.handle.net/10541/622582
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz244.026en
dc.titlePharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumoursen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-01-21T19:52:49Z


Files in this item

Thumbnail
Name:
mdz244.026.pdf
Size:
87.92Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract

This item appears in the following Collection(s)

Show simple item record